Pinkerton Wealth LLC Makes New Investment in Insmed, Inc. $INSM

Pinkerton Wealth LLC purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,148 shares of the biopharmaceutical company’s stock, valued at approximately $896,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. ABN Amro Investment Solutions purchased a new position in Insmed in the 4th quarter worth approximately $1,738,000. PSP Research LLC purchased a new stake in shares of Insmed in the 4th quarter valued at $531,000. Atle Fund Management AB purchased a new stake in shares of Insmed in the 4th quarter valued at $4,851,000. Banque Cantonale Vaudoise purchased a new stake in shares of Insmed in the 4th quarter valued at $316,000. Finally, Berbice Capital Management LLC boosted its stake in shares of Insmed by 133.3% in the 4th quarter. Berbice Capital Management LLC now owns 700 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 400 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Bank of America upped their price objective on shares of Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Jefferies Financial Group began coverage on shares of Insmed in a report on Monday, March 16th. They set a “buy” rating and a $228.00 price target for the company. Finally, Royal Bank Of Canada lowered their price target on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating for the company in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $210.95.

Insmed Trading Up 0.5%

Shares of NASDAQ INSM opened at $107.91 on Thursday. Insmed, Inc. has a 1 year low of $64.85 and a 1 year high of $212.75. The stock has a market cap of $23.39 billion, a P/E ratio of -18.77 and a beta of 0.89. The firm has a 50-day moving average of $139.24 and a 200 day moving average of $161.82. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The company had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. Insmed’s revenue was up 229.7% on a year-over-year basis. During the same period last year, the company posted ($1.42) EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Insider Activity

In other Insmed news, COO Roger Adsett sold 88,060 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer owned 106,810 shares in the company, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the sale, the insider owned 51,871 shares in the company, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 150,494 shares of company stock valued at $23,846,784 in the last 90 days. 2.10% of the stock is currently owned by insiders.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.